Contact
searchSearch
HMP Global
Login

Multiple Myeloma Resource Center

News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
From Oncology
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
From Oncology
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guidelines for Multiple Myeloma
01/11/2023
Yvette C. Terrie, BS Pharm, RPh
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published...
01/11/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways

Expert Insights

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways
Thomas Martin, MD, UCSF
Interview
Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial
03/30/2022
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses...
03/30/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
Comparative Effectiveness of KRd Versus VRd for Newly Diagnosed MM
ENGAGING EXPERTS
Comparative Effectiveness of KRd Versus VRd for Newly Diagnosed MM
08/27/2020
08/27/2020
Journal of Clinical Pathways
Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways

Newsfeed

News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
Conference Coverage
BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma
12/12/2022
Craig Ostroff
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Isatuximab + Carfilzomib and Dexamethasone in Early vs Late Relapsed Multiple Myeloma
12/12/2022
Katie Herman
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma
12/11/2022
Katie Herman
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP,...
12/11/2022
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
Conference Coverage
Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact
09/10/2025
Grace Taylor, MS, MA
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session,...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Building a Transparent Framework for Predictable Cost of Care in Oncology Pathways
09/10/2025
Hannah Musick
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Reviewing a Decade of Oncology Pathways: Standardization, Gaps, and the Road to Real-Time Intelligence
09/09/2025
Hannah Musick
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
AI as a Thought Partner: Reframing Innovation in Medicine and Practice Management
09/09/2025
Grace Taylor, MS, MA
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx,...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
How AI is Reshaping Clinical Practice, Governance, and Patient Trust
09/09/2025
Grace Taylor, MS, MA
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
From Dispensing to Decision-Making: How Pharmacists Are Redefining Leadership in Oncology Care
09/08/2025
Grace Taylor, MS, MA
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Theranostics: Clinical Promise, Operational Hurdles, and the Road Ahead
09/08/2025
Hannah Musick
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Scaling Bispecifics and CAR T-Cell Therapy in Community Oncology: From Promise to Practice
09/08/2025
Hannah Musick
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Practical Insights for Embedding Whole-Person Care into Clinical Pathways
09/08/2025
Juliet Gallagher
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025...
09/08/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Safety and Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
04/06/2022
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world...
04/06/2022
Journal of Clinical Pathways
Quiz
Quiz: Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM
12/01/2021
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation...
12/01/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Belantamab Mafodotin for Relapsed/Refractory MM
10/14/2021
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab...
10/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Daratumumab for MM
09/09/2021
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding...
09/09/2021
Journal of Clinical Pathways
Quiz
Quiz: Daratumumab Among Patients With MM
07/19/2021
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based...
07/19/2021
Journal of Clinical Pathways
Quiz
Quiz: DRd vs Rd for Newly Diagnosed MM
03/12/2021
03/12/2021
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use